In November 2020, Dr. Peter McCullough published the multi-drug outpatient COVID-19 treatment protocol in the American Journal of Medicine

Overview Debates Related claims Topics

The ICON study published in the journal Chest demonstrated a greater than 50% reduction in mortality among hospitalized COVID-19 patients treated with ivermectin

The Federal Trade Commission sued Nate Jones and Xlear Corporation over marketing and studies of nasal sprays and gargles against SARS-CoV-2

The Federal Trade Commission took regulatory action against Dr. Eric Nepute regarding clinical claims about vitamin D and COVID-19

In 2021, the American Medical Association issued an official policy statement calling for the cessation of ivermectin prescriptions for COVID-19

Drs. Paul Marik, Robert Apter, and Mary Talley Bowden filed a federal lawsuit against the United States Food and Drug Administration regarding its public statements on ivermectin

The World Health Organization and the European Society of Intensive Care Medicine issued recommendations in November 2020 advising against the use of remdesivir for COVID-19

On the day before the 2026 midterm election, the White House issued a press release highlighting drops in prescription drug prices resulting from Donald Trump's policies

Generation of reactive metabolites during medication metabolism is a compound-specific risk factor for liver toxicity

Intrinsic drug-induced liver injury is dose-dependent and predictable

Idiosyncratic drug-induced liver injury is unpredictable and generally not related to dose

Susceptibility to idiosyncratic drug-induced liver injury has a genetic component

Drug-induced liver injury is broadly classified into intrinsic and idiosyncratic forms

Oncological agents, specifically immune checkpoint inhibitors and tyrosine kinase inhibitors, represent an increasing cause of idiosyncratic drug-induced liver injury

Corticosteroids serve as the mainstay of medical therapy for immune checkpoint inhibitor-induced liver injury

A higher medication dose is a risk factor for drug-induced liver injury

Idiosyncratic drug-induced liver injury from phenytoin or trimethoprim-sulfamethoxazole can present with DRESS syndrome, featuring fever, rash, and eosinophilia

Prompt discontinuation of the suspected causative agent is a critical intervention in the management of drug-induced liver injury

A short course of corticosteroids can be used to treat autoimmune-like drug-induced liver injury caused by nitrofurantoin or minocycline

Reported cases of cholestatic drug-induced liver injury caused by anabolic steroids have decreased as of November 2026

The latency period between starting a causative medication and the manifestation of drug-induced liver injury is typically three to six months